medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2021, Number 4

<< Back Next >>

An Med Asoc Med Hosp ABC 2021; 66 (4)

Extraosseous Ewing's sarcoma

Hinojosa GJ, Villalobos PA, Hernández MOR

Language: Spanish
References: 28
Page: 283-287
PDF size: 295.28 Kb.


ABSTRACT

Primary bone tumors are rare, representing only 5% of all tumors in adolescents and young adults. Of this group, the second place is occupied by osseous and extraosseous Ewing's sarcoma. Histologically it is characterized by presenting small, round and blue cells. Symptoms are directly related to the location and size of the tumor. In general, treatment is based on chemotherapy followed by local therapy (surgery and/or radiotherapy) and again chemotherapy. Clinical case: a 70-year-old woman was presented with a tumor in the right groin with progressive and accelerated growth. A hematological neoplasm was suspected and a 45 mm soft tissue mass in the right groin region with a standardized uptake value max of 9.8 was found on PET CT. A surgical resection was performed and in the histopathological study reported a lymph node infiltrated by a primitive neuroectodermal tumor/Ewing's sarcoma. After that, the patient was treated with postoperative radiotherapy. Extraosseous Ewing's sarcoma is a rare disease; in general, these patients have a better prognosis than patients with osseous Ewing's sarcoma. As there is little evidence of treatment, it must be individualized and therefore subjected to a multidisciplinary approach.


REFERENCES

  1. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol. 2010; 11 (2): 184-192.

  2. Rekhi B, Vogel U, Basak R, Desai SB, Jambhekar NA. Clinopathological and molecular Spectrum of Ewing Sarcomas/PNET's, including validation of EWSR1 rearrangement by conventional and array FISH technique in certain cases. Pathol Oncol Res. 2014; 20 (3): 503-516.

  3. Choi EY, Gardner JM, Lucas DR, McHugh JB, Patel RM. Ewing sarcoma. Semin Diagn Pathol. 2014; 31 (1): 39-47.

  4. Rizo P, Sierra M, Vázquez G, Cano M, Meneses A, Mohar A. Registro hospitalario de cáncer: compendio de cáncer 2000-2004. Cancerología. 2007; 2: 203-287.

  5. Esiashvili N, Goodman M, Marcus RB Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J Pediatr Hematol Oncol. 2008; 30 (6): 425-430.

  6. Jawad MU, Cheung MC, Min ES, Schneiderbauer MM, Koniaris LG, Scully SP. Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1,631 cases from the SEER database, 1973-2005. Cancer. 2009; 115 (15): 3526-3536.

  7. Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA et al. Ewing's sarcoma family of tumors: current management. Oncologist. 2006; 11 (5): 503-519.

  8. Applebaum MA, Worch J, Matthay KK, Goldsby R, Neuhaus J, West DC, Dubois SG. Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer. 2011; 117 (13): 3027-3032.

  9. Cheung CC, Kandel RA, Bell RS, Methews RE, Ghazarian MD. Extraskeletal Ewing sarcoma in a 77-years-old woman. Arch Pathol Lab Med. 2001; 125 (10): 1358-1360.

  10. Geens L, Van Robays J, Geert V, Van der Speeten K. An unusual location of extraosseous Ewing's sarcoma. Case Rep Oncol. 2013; 6 (2): 293-302.

  11. Leavey PJ, Collier AB. Ewing sarcoma: prognostic criteria, outcomes and future treatment. Expert Rev Anticancer Ther. 2008; 8 (4): 617-624.

  12. NCCN Guidelines Version 1.2020 Bone Cancer.

  13. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29 (Suppl 4): iv79-iv95.

  14. Grier HE, Krallo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003; 348 (8): 694-701.

  15. Kolb EA, Kushner BH, Gorlick R, Lavardiere C, Healey JH, LaQuaglia MP et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol. 2003; 21 (18): 3423-3430.

  16. Schuck A, Ahrens S, Paulussen M, Kuhlen M, Konemann S, Rübe C et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2003; 55 (1): 168-177.

  17. Jurgens H, Gobel V, Michaelis J, Ramach W, Ritter J, Sauer R. The Cooperative Ewing Sarcoma Study CESS 81 of the German Pediatric Oncology Society analysis after 4 years. Klin Padiatr. 1985; 197 (3): 225-232.

  18. Dunst J, Jurgens H, Sauer R, Pape H, Paulussen M, Winkelmann W, Rübe C. Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial. Int J Radiat Oncol Biol Phys. 1995; 32 (4): 919-930.

  19. Paulussen M, Ahrens S, Braun–Munzinger G, Craft AW, Dockhorn-Dworniczak, Dorffel W et al. EICESS 92 (European Intergroup Cooperative Ewing's Sarcoma Study) – preliminary results. Klin Padiatr. 1999; 211 (4): 276-283.

  20. Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment-cyclophosphamide compared with ifosfamide in standard risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008; 26 (27): 4385-4393.

  21. Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol. 2009; 27 (15): 2536-2541.

  22. O'Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002; 359 (9325): 2235-2241.

  23. Biswas B, Shukla NK, Deo S, Agarwala S, Sharma D, Vishnubhatla S et al. Evaluation of outcome and prognostic factors in extraosseous Ewing sarcoma. Pediatr Blood Cancer. 2014; 61: 1925-1931.

  24. Cash T, McIlvaine E, Krailo MD, Lessnick SL, Lawlor ER, Laack N et al. Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2016; 63 (10): 1771-1779. doi: 10.1002/pbc.26096.2016 14.

  25. Orr WS, Denbo JW, Billups CA, Wu J, Navid F, Rao BN, Davidoff AM, Krasin MJ. Analysis of prognostic factors in extraosseous Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital experience. Ann Surg Oncol. 2012; 19 (12): 3816-3822.

  26. Raney R, Asmar L, Newton W, Bagwell C, Breneman J, Gehan E et al. Ewing's sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991. J Clin Oncol. 1997; 15 (2): 574-582.

  27. Castex MP, Rubie H, Stevens M, Escribano C, Gauzy J, Brouchet A et al. Extraosseus localized Ewing tumors: improved outcome with anthracyclines –The French Society of Pediatric Oncology and International Society of Pediatric Oncology. J Clin Oncol. 2007; 25: 1176-1182.

  28. Donaldson SS. Ewing sarcoma: radiation dose and target volumen. Pediatr Blood Cancer. 2004; 42 (5): 471-476.




2020     |     www.medigraphic.com